January 24, 2020
Rose
Federal prosecutors have said that Insys, based in Arizona, embarked on an intensive marketing plan — including paying doctors for sham educational talks and luring others with lap dances — to sell its under-the-tongue fentanyl spray, Subsys, which was federally approved to treat patients with cancer. Meanwhile, McKesson has reached a settlement with its investors over allegations it missed suspicious opioid shipments.
from Kaiser Health News https://ift.tt/37r8yaS
January 24, 2020
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Even If Louisiana Governor Is Ousted By GOP Rival, His Hallmark Medicaid Expansion Likely Isn’t Going Anywhere- The Politics Of Purdue Pharma Settlement: Dems Want To Gamble For Larger Amount, GOP Favors Quick Resolution
- Success Of A Polypill With Cocktail Of Heart Meds Made Headlines, But Will U.S. Doctors Actually Embrace It?
- How Libraries Have Become Public Health Hubs In The Middle Of Rural Health Deserts
- FDA’s Warnings Over What Genetic Testing Companies Can Report To Patients Deemed ‘Troubling’ By Industry Group
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment